- Companies
- Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Valuation Multiples
Zentalis Pharmaceuticals is valued at $169M as of November 2026. In the last 12 months, Zentalis Pharmaceuticals EBITDA was ($175M).
Zentalis Pharmaceuticals Overview
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Founded
2014
HQ
Employees
166
Website
Financials (LTM)
EV
$28M
Valuation Multiples
Start free trialZentalis Pharmaceuticals Financials
Zentalis Pharmaceuticals reported last 12-month revenue of - and negative EBITDA of ($175M).
In the same LTM period, Zentalis Pharmaceuticals generated - in gross profit, ($175M) in EBITDA losses, and had net loss of ($157M).
Revenue (LTM)
Zentalis Pharmaceuticals P&L
In the most recent fiscal year, Zentalis Pharmaceuticals reported revenue of - and EBITDA of ($136M).
Zentalis Pharmaceuticals is unprofitable as of last fiscal year, with gross margin of -, EBITDA margin of -, and net margin of -.
Financial data powered by Morningstar, Inc.
Zentalis Pharmaceuticals Stock Performance
Zentalis Pharmaceuticals has current market cap of $169M, and enterprise value of $28M.
Market Cap Evolution
Zentalis Pharmaceuticals' stock price is $1.72.
Zentalis Pharmaceuticals share price decreased by 12.2% in the last 30 days, and increased by 20.3% in the last year.
Zentalis Pharmaceuticals has an EPS (earnings per share) of $-1.40.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $28M | $169M | 0.0% | -12.2% | -54.4% | 20.3% | $-1.40 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialZentalis Pharmaceuticals Valuation Multiples
Zentalis Pharmaceuticals trades at (0.2x) EV/EBITDA.
EV / Revenue (LTM)
Zentalis Pharmaceuticals Financial Valuation Multiples
As of November 8, 2026, Zentalis Pharmaceuticals has market cap of $169M and EV of $28M.
Zentalis Pharmaceuticals has a P/E ratio of (1.1x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Zentalis Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Zentalis Pharmaceuticals Margins & Growth Rates
Zentalis Pharmaceuticals grew EBITDA by 31% in the last fiscal year.
Zentalis Pharmaceuticals Margins
Zentalis Pharmaceuticals Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Zentalis Pharmaceuticals Operational KPIs
Zentalis Pharmaceuticals' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.9M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Zentalis Pharmaceuticals Competitors
Zentalis Pharmaceuticals competitors include Nextbiomedical Co, TYK Medicines, PegBio, PepGen, Invivyd, Compugen, Searle Co., BridgeBio Oncology, Mayne Pharma Group and S Biomedics.
Most Zentalis Pharmaceuticals public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $12M | ($260K) | 12.1x | 10.2x | (568.5x) | (39.7x) | |||
| - | ($40M) | - | - | (4.0x) | - | |||
| - | ($31M) | - | - | (4.3x) | - | |||
| - | ($88M) | - | - | (0.8x) | - | |||
| $53M | ($50M) | 0.3x | 0.2x | (0.3x) | (0.1x) | |||
| $73M | $31M | 0.8x | 3.1x | 1.9x | - | |||
| $133M | $21M | 1.5x | 1.4x | 9.1x | 5.4x | |||
| - | ($145M) | - | - | - | - | |||
This data is available for Pro users. Sign up to see all Zentalis Pharmaceuticals competitors and their valuation data. Start Free Trial | ||||||||
Zentalis Pharmaceuticals VC Funding History
Before going public, Zentalis Pharmaceuticals raised $263M in total equity funding, across 3 rounds.
Zentalis Pharmaceuticals Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Zentalis Pharmaceuticals
| When was Zentalis Pharmaceuticals founded? | Zentalis Pharmaceuticals was founded in 2014. |
| Where is Zentalis Pharmaceuticals headquartered? | Zentalis Pharmaceuticals is headquartered in United States. |
| How many employees does Zentalis Pharmaceuticals have? | As of today, Zentalis Pharmaceuticals has over 166 employees. |
| Who is the CEO of Zentalis Pharmaceuticals? | Zentalis Pharmaceuticals' CEO is Julie M. Eastland. |
| Is Zentalis Pharmaceuticals publicly listed? | Yes, Zentalis Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Zentalis Pharmaceuticals? | Zentalis Pharmaceuticals trades under ZNTL ticker. |
| When did Zentalis Pharmaceuticals go public? | Zentalis Pharmaceuticals went public in 2020. |
| Who are competitors of Zentalis Pharmaceuticals? | Zentalis Pharmaceuticals main competitors include Nextbiomedical Co, TYK Medicines, PegBio, PepGen, Invivyd, Compugen, Searle Co., BridgeBio Oncology, Mayne Pharma Group, S Biomedics. |
| What is the current market cap of Zentalis Pharmaceuticals? | Zentalis Pharmaceuticals' current market cap is $169M. |
| Is Zentalis Pharmaceuticals profitable? | No, Zentalis Pharmaceuticals is not profitable. |
| What is the current EBITDA of Zentalis Pharmaceuticals? | Zentalis Pharmaceuticals has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Zentalis Pharmaceuticals? | Current EBITDA multiple of Zentalis Pharmaceuticals is (0.2x). |
| How many companies Zentalis Pharmaceuticals has acquired to date? | Zentalis Pharmaceuticals hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Zentalis Pharmaceuticals has invested to date? | Zentalis Pharmaceuticals hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Zentalis Pharmaceuticals
Lists including Zentalis Pharmaceuticals
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




